- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.11. | Prenetics Global Limited: Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth | 278 | GlobeNewswire (Europe) | IM8's Strong Unit Economics-60% Margins and 3.9-Month Payback-Central to Cantor's Bullish Outlook Cantor Notes PRE's ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company's Financial... ► Artikel lesen | |
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 12.11. | Cantor Fitzgerald lowers Prenetics stock price target to $31 on Q3 results | 2 | Investing.com | ||
| 10.11. | Prenetics Global GAAP EPS of -$0.53, revenue of $23.6M | 3 | Seeking Alpha | ||
| 10.11. | Prenetics Global Limited: Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR by December 2025, Fastest Supplement Brand Growth in Industry History | 81 | GlobeNewswire (Europe) | Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M... ► Artikel lesen | |
| 10.11. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.11. | Prenetics Global's Earnings: A Preview | 1 | Benzinga.com | ||
| 04.11. | Prenetics' IM8 achieves record $9M in revenue for October | 3 | Seeking Alpha | ||
| 31.10. | Prenetics acquires 100 bitcoin following $44M equity raise | 3 | Seeking Alpha | ||
| 31.10. | Prenetics Global Limited: Prenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR | 187 | GlobeNewswire (Europe) | Additional Bitcoin Acquisition Follows Immediately on $44 Million Equity OfferingCompany now holds a total of 378 BTC (valued at ~$41 Million)CHARLOTTE, N.C., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Prenetics... ► Artikel lesen | |
| 29.10. | Prenetics Global Limited: Prenetics CEO Danny Yeung Publishes "The Dual-Engine Revolution" Manifesto: A Blueprint for the Future of Health + Wealth | 2 | GlobeNewswire (USA) | ||
| 28.10. | Prenetics Global Limited: Prenetics Announces Closing of Approx. $44.0 Million Equity Offering to Fuel IM8's Global Expansion and Bitcoin Treasury Strategy | 4 | GlobeNewswire (USA) | ||
| 28.10. | Nasdaq-notiertes Unternehmen Prenetics sammelt $48 Millionen ein, um Bitcoin zu kaufen | 4 | Newsbit | ||
| 27.10. | David Beckham-verbundenes Prenetics greift auf Prominente und Krypto-Titanen bei einer $48M-Finanzierung für Bitcoin-Schatz zurück | 2 | Bitcoin.com News | ||
| 27.10. | Prenetics Oversubscribes Offering | - | Baystreet.ca | ||
| 27.10. | Prenetics raises $48 million in public offering to fuel IM8 growth | 3 | Investing.com | ||
| 27.10. | Kapitalerhöhung über 48 Mio. Dollar: Aktie von Prenetics Global stürzt ab | 2 | Investing.com Deutsch | ||
| 27.10. | Prenetics Global stock falls after pricing $48 million public offering | 1 | Investing.com | ||
| 27.10. | Prenetics Global Limited: Prenetics Announces Oversubscribed Approximately $48 Million Equity Offering with Potential for $216 Million in Total Proceeds to Fuel IM8's Global Expansion and Bitcoin Treasury Strategy | 1 | GlobeNewswire (USA) | ||
| 27.10. | Prenetics prices $48 million public offering of shares and warrants | 2 | Investing.com |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CANSINO BIOLOGICS | 4,442 | +1,32 % | CanSino Biologics Inc: Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle | HONG KONG, Aug 20, 2025 - (ACN Newswire) - In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades... ► Artikel lesen | |
| SINO BIOPHARM | 0,740 | -1,70 % | SINO BIOPHARM (01177): VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON LM-350 "CDH17 ADC" APPROVED BY THE NMPA | ||
| GENSCRIPT BIOTECH | 1,802 | +7,42 % | GENSCRIPT BIO (01548): NEXT DAY DISCLOSURE RETURN | ||
| QUANTUM-SI | 1,275 | +3,66 % | Quantum-Si stock rating reiterated by H.C. Wainwright on Proteus potential | ||
| INNOVENT BIOLOGICS | 9,650 | -3,02 % | Innovent Biologics' Mazdutide Phase 3 Trial In Obesity Achieves Primary & Key Secondary Endpoints | INDIANAPOLIS (dpa-AFX) - Innovent Biologics, Inc. (IVBXF, 1801.HK) announced that the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1)... ► Artikel lesen | |
| SCILEX | 21,930 | +16,96 % | Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc. | ||
| ORIGIN AGRITECH | 0,980 | -5,77 % | Origin Agritech Limited: Origin Agritech Obtains New Licenses for Crop Seed Production and GMO Business Operations | Strategic Restructuring Positions Company to Strengthen Market Presence with Expanded Operational Capabilities
BEIJING, Oct. 24, 2025 /PRNewswire/ -- Origin Agritech... ► Artikel lesen | |
| AKESO | 11,800 | -4,06 % | Akeso, Inc.: Akeso's Bispecific Antibody Targeting Aß and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China | HONG KONG, Nov. 16, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aß) and... ► Artikel lesen | |
| NUVALENT | 105,88 | -1,97 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,56 | -0,13 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| QIAGEN | 40,380 | +2,38 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,170 | +8,45 % | Recursion (RXRX) Jumps 8% on Bargain-Hunting | ||
| BIONTECH | 83,05 | +0,06 % | Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson? | Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert Vidac Pharma mehr und mehr... ► Artikel lesen | |
| JANUX THERAPEUTICS | 28,800 | +0,73 % | Wolfe Research initiates Janux Therapeutics stock with Peerperform rating | ||
| PRAXIS PRECISION MEDICINES | 169,78 | +3,33 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat |
Das Unternehmen PRENETICS GLOBAL LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,62 % bei einem Aktienkurs von 12,830 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.